Loading...
Changes in weight associated with telotristat ethyl in the treatment of carcinoid syndrome.
Weickert, M Kaltsas, G Hörsch, D Lapuerta, P Pavel, M Caplin, M Bergsland, E Kunz, P Anthony, L
Weickert, M
Kaltsas, G
Hörsch, D
Lapuerta, P
Pavel, M
Caplin, M
Bergsland, E
Kunz, P
Anthony, L
Citations
Altmetric:
Abstract
In the placebo-controlled Phase III TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome) trial, the oral tryptophan hydroxylase inhibitor telotristat ethyl significantly reduced bowel movement (BM) frequency during a 12-week, double-blind treatment period in 135 patients with metastatic neuroendocrine tumors with carcinoid syndrome and ≥4 BMs per day. Patients (mean [SD] age, 63.5 [8.9] years; mean [SD] body mass index, 24.9 [4.9] kg/m2) received placebo, telotristat ethyl 250 mg, or telotristat ethyl 500 mg 3 times per day (TID) in addition to somatostatin analogue therapy. Weight loss is associated with uncontrolled carcinoid syndrome and may be associated with reduced survival.
Description
Date
2018-06
Publisher
Collections
Files
Keywords
Type
Article
Citation
Changes in weight associated with telotristat ethyl in the treatment of carcinoid syndrome. 2018, 40(6): 952-962.e2 Clin Ther